Dallas, Texas – October 31, 2023 — A critical component to enhancing the LexaGene Life Sciences (“LexaGene”) MiQLab® System is a renewal of the license for the use of certain technologies developed by LexaGene Life Science’s Chief Technology Officer Dr. Jack Regan and others at the Lawrence Livermore National Laboratory (“LLNL”). These patented technologies are critical to the operation and differentiation of the MiQLab® System. We are pleased to announce that LexaGene has successfully negotiated and executed a new licensing agreement with Lawrence Livermore National Security, LLC (“LLNS”), the licensing arm of LLNL, for the exclusive use of these technologies. LexeGenes’ rights to use the LLNL IP are subject to the continuation of and compliance with the terms of the license, of which Life Sciences remains in full compliance of such terms.
For more information about LexaGene and the MiQLab System, please visit www.lexagenelifesciences.com
LexaGene Life Sciences, LLC
LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry.